Clinical Trials
Doctors Poulos and Fisher, and the entire team of dermatologists at Kingsway Dermatology strongly believe that being at the forefront of medical research is a vital part of their practice.
In keeping with our mission to provide outstanding patient care, Kingsway Clinical Research was established in 2014, as a division of Kingsway Dermatology, that specializes in clinical trials in collaboration with Probity Medical Research.
Our goal is to help bring safe and effective cutting edge treatments to our patients. This work allows our patients access to medications, sometimes years ahead of the commercial launch. It also allows our patients access to medications that may not be covered under insurance programs.
Why choose Kingsway Clinical Research?
- Trusted reputation of our team of experienced, Board certified Dermatologists, with experience in clinical trials
- Our research centre is interconnected with a busy dermatology clinic with a large and non-transient patient population
- Conveniently located – right across the Islington subway station, 10 km from St. Joseph’s Hospital, and 12 km from Toronto Pearson International Airport
- Presence of investigators while study patients are scheduled
- Assurance of strictest patient confidentiality, privacy and professionalism
Why volunteer for clinical trials?
Access to alternative treatments and novel drugs
Taking an active role in your health care
Comprehensive medical care from overseeing physician and dedicated clinical trials staff
Opportunity to contribute to advancements in medical research
No cost on your part and compensation for travel associated with the study is available
Current and Upcoming Trials
Join our clinical trials now for free, early access to the latest dermatology treatments! If you’re interested in helping our trusted team, contact our clinical trials coordinator at (416) 231-0100, extension 212, or email cl**********************@ki*****************.com.
ATOPIC DERMATITIS
Phase 3 Research Trial for Atopic Dermatitis – Eczema 2 (40 Weeks)
Adults aged 18 and over with a diagnosis of atopic dermatitis (AD) that has been present for at least 6 months, are needed for a research trial. To qualify for the study, individuals must have moderate to severe eczema with involvement of 10% or more body surface area (BSA), and a history of inadequate response to topical corticosteroids (TCS) of medium to higher potency within 6 months, or for whom topical treatments are otherwise medically inadvisable. Participants will receive an investigational medication (active study drug) or placebo via injection. Study medication and study-related assessments will be provided at no cost. Reimbursement for study-related expenses will be provided. Study participation will last about 40 weeks and involve about 11 visits to the study centre.
If you would like to participate or would simply like to learn more, please contact our clinical trials coordinator.
ABDOMINAL FAT STUDY
Details to follow.
Study medication and study-related assessments will be provided at no cost. Reimbursement for reasonable study-related expenses will also be provided.
If you would like to participate or would simply like to learn more, please contact our clinical trials coordinator.
Ongoing Trials (Enrollment is closed)
ATOPIC DERMATITIS
- Open label, long term extension trial to evaluate the efficacy and safety of Tralokinumab in subjects with atopic dermatitis
- A Phase 3 Randomized, Placebo-Controlled, Double-blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
- A phase 3 long-term extension study investigating the efficacy and safety of Abrocitinib, Administered to subjects aged 12 years and older with moderate to severe atopic dermatitis
- A phase 3 extension trial of DELTA 1 and DELTA 2 to evaluate the long-term safety of a twice-daily treatment with delgocitinib cream 20 mg/g as needed for up to 36 weeks in adult subjects with chronic hand eczema (DELTA 3)
PSORIASIS
- Phase 3 open label study to assess the safety and efficacy of Risankizumab for maintenance in moderate to severe plaque psoriasis
VITILIGO
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 Followed by an Extension Period in Participants With Vitiligo
ALOPECIA AREATA
- A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients with Moderate to Severe Alopecia Areata
COMPLETED TRIALS
ACNE
- A safety and efficacy study to compare dapsone dermal gel with vehicle control in patients with acne vulgaris
ATOPIC DERMATITIS
- Double blind, vehicle-controlled Phase IIb study to assess the safety and efficacy of topically applied DS107 cream in mild to moderate atopic dermatitis
- Phase 3 confirmatory study investigating efficacy and safety of dupilumab monotherapy in adults with moderate to severe atopic dermatitis
- Phase 3 double blind, placebo-controlled study investigating the efficacy and safety of multiple Dupilumab dose regimens for maintaining response in patients with atopic dermatitis
- Open label study of Dupilumab in patients with atopic dermatitis
- Tralokinumab monotherapy for adults with moderate to severe atopic dermatitis
- Double blind, placebo-controlled study to evaluate the efficacy and safety of Barictinib in adults with moderate to severe atopic dermatitis
- Open label, phase 3 study to evaluate efficacy and safety of Bariticinib in adults with moderate to severe atopic dermatitis
PSORIASIS
- Canadian Humira post-marketing observational epidemiological study assessing effectiveness in psoriasis
- Phase 3 study to evaluate the efficacy and safety of Brodalumab compared with placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis
- Open label study to assess the safety of Etanercept in subjects with plaque psoriasis
- Risankizumab versus placebo in patients with moderate to severe plaque psoriasis
- Double blind study of Secukinumab to demonstrate efficacy compared to Ustekinumab in subjects with moderate to severe plaque psoriasis
- Double blind, active-control study to compare efficacy and safety of CHS-1420 versus Humira in subjects with chronic plaque psoriasis
- Double blind study assessing short and long term efficacy, safety and tolerability of Secukinumab in subjects of body weight 90 kg or higher with moderate to severe plaque psoriasis
- A Phase 3 Efficacy and safety study of Taparinof for the treatment of plaque psoriasis in adults
- A Phase 3, Multicenter, Randomized, Double Blind Study Evaluating the Efficacy and Safety of ABP654 Compared with Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis
- A Multicenter, Randomized, Double-blind Study Evaluating the Pharmacokinetics, Efficacy,Safety, and Immunogenicity of Multiple Switches Between Humira®(adalimumab [US]) and ABP 501 Compared With Continued Use of Adalimumab in Subjects With Moderate to Severe Plaque Psoriasis
VITILIGO
- Phase 3 Double-blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib cream Followed by an Extension period in Participants with Vitiligo
- A Double-blind, Vehicle-controlled Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants with Vitiligo
Patient testimonials
